Solid Biosciences (SLDB) analyst forecast and price target
Analyst forecast
Consensus of 12 analyst ratings
Based on 4 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| RBC Capital | Initiated Coverage | Outperform | $18.00 | Sep 16, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $25.00 | Sep 14, 2026 |
| Cantor Fitzgerald | Maintained | Overweight | $26.00 from $16.00 | Aug 27, 2026 |
| Truist Securities | Maintained | Buy | $20.00 from $16.00 | Aug 21, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $25.00 from $20.00 | Jun 3, 2026 |
| Wedbush | Maintained | Outperform | $16.00 | May 18, 2026 |
| Piper Sandler | Maintained | Overweight | $18.00 from $17.00 | May 13, 2026 |
| Wedbush | Maintained | Outperform | $16.00 from $17.00 | May 13, 2026 |
| JP Morgan | Maintained | Overweight | $12.00 from $11.00 | Mar 25, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $20.00 | Mar 23, 2026 |
| Needham | Maintained | Buy | $19.00 | Mar 20, 2026 |
| Chardan Capital | Maintained | Buy | $15.00 | Mar 20, 2026 |
| Guggenheim | Initiated Coverage | Buy | $26.00 | Mar 20, 2026 |
| Chardan Capital | Maintained | Buy | $15.00 | Mar 12, 2026 |
| Wedbush | Maintained | Outperform | $17.00 from $14.00 | Mar 12, 2026 |
| Wedbush | Maintained | Outperform | $14.00 | Mar 11, 2026 |
| Needham | Maintained | Buy | $16.00 | Feb 9, 2026 |
| Needham | Maintained | Buy | $16.00 | Jan 14, 2026 |
| Needham | Initiated Coverage | Buy | $16.00 | Dec 4, 2025 |
| JP Morgan | Maintained | Overweight | $11.00 from $13.00 | Nov 5, 2025 |
Frequently asked questions
What is the price target for SLDB stock?
The average 12-month analyst price target for Solid Biosciences (SLDB) is $22.25, with a high estimate of $26.00 and a low of $18.00, across 4 analysts.
Is SLDB a buy, sell, or hold?
Analysts covering Solid Biosciences currently average a Buy rating: 12 buy, 0 hold and 0 sell, from 12 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for SLDB?
The average price target of $22.25 implies 282.30% upside from the last price of $5.82.
What is the latest analyst rating on SLDB?
On Sep 16, 2026, RBC Capital initiated coverage of Solid Biosciences at Outperform with a price target of $18.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.